Quick Facts

Chemical Name
Growth Hormone Releasing Factor (1-44) with Trans-3-Hexenoic Acid
Also Known As
Egrifta, TH9507
Category
Growth Hormone
Administration
Daily subcutaneous injection, typically in the abdomen

What is Tesamorelin?

Tesamorelin is a synthetic analog of human GHRH that contains all 44 amino acids plus a trans-3-hexenoic acid modification that improves stability. It is FDA-approved (as Egrifta) for the treatment of lipodystrophy in HIV patients, making it one of the few peptides with full regulatory approval. Research has demonstrated significant reductions in visceral adipose tissue with its use.

How Does Tesamorelin Work?

Tesamorelin binds to GHRH receptors on the pituitary gland with similar affinity to natural GHRH. The trans-3-hexenoic acid modification at the N-terminus increases its resistance to enzymatic degradation while preserving full biological activity. By stimulating GH release, it indirectly elevates IGF-1 levels, which contributes to its metabolic effects including reduction of visceral fat.

Research-Backed Benefits

Visceral Fat Reduction

Strong Evidence

FDA-approved for reducing trunk fat accumulation with clinically proven efficacy.

Metabolic Improvement

Strong Evidence

May improve triglyceride levels and other metabolic markers.

Cognitive Function

Moderate Evidence

Research suggests potential benefits for cognitive function in older adults.

Natural GH Stimulation

Strong Evidence

Promotes physiological GH release while maintaining feedback mechanisms.

Body Composition

Moderate Evidence

May improve overall body composition beyond just visceral fat.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
2 mg daily
Frequency
Once daily
Duration
Minimum 12 weeks for visible fat reduction

FDA-approved dosing is 2mg daily subcutaneous injection.

Side Effects & Safety

  • Injection site reactions
  • Arthralgia (joint pain)
  • Peripheral edema
  • Paresthesia (tingling)

Frequently Asked Questions

Yes, Tesamorelin (brand name Egrifta) is FDA-approved for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.
Clinical trials showed an average 15-18% reduction in visceral adipose tissue over 26 weeks of treatment.
Tesamorelin contains all 44 amino acids of natural GHRH plus a stabilizing modification. It's the only GHRH analog with full FDA approval.

References

  1. Falutz J, et al. "Tesamorelin for the treatment of lipodystrophy." New England Journal of Medicine, 2007. PMID: 17989381

Get the Complete Tesamorelin Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research